The ICR responds to NICE’s recommendation not to approve abiraterone as first-line treatment for advanced prostate cancer 15 Jul 2021 The Institute of Cancer Research, London, is disappointed at the decision by NICE not to recommend abiraterone as a first-line NHS treatment for newly diagnosed, advanced prostate cancer. Find out more Show/Hide
Advanced radiotherapy ‘must play central role’ in clearing Covid’s cancer backlog 12 Apr 2021 Urgent investment is needed in advanced forms of radiotherapy so the high-tech treatment can play a central role in clearing the backlog in NHS cancer care that has built up during the pandemic. Find out more Show/Hide
ICR welcomes NICE’s decision to reassess abiraterone as first-line treatment for advanced prostate cancer 29 Oct 2020 The Institute of Cancer Research, London, has welcomed the announcement by NICE that it will reconsider its decision not to recommend abiraterone as a first-line treatment for newly diagnosed, advanced prostate cancer. Find out more Show/Hide
ICR welcomes approval of immunotherapy for head and neck cancer in Scotland but warns of ‘home nations lottery’ 07 Sep 2020
Approval of targeted therapies first line for prostate cancer ‘will ease COVID-19 pressures’ 06 May 2020
The ICR responds to decision by NICE not to recommend pembrolizumab as first-line treatment for advanced head and neck cancer 15 Jan 2020
The ICR responds to approval of abiraterone as first-line treatment for advanced prostate cancer on the NHS in Scotland 13 Jan 2020
ICR responds to NICE approval of palbociclib for treating advanced breast cancer after hormone therapy 28 Nov 2019